This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Reference
Wolfson LJ, et al. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model. PLOS One : 13 Aug 2019. Available from: URL: https://doi.org/10.1371/journal.pone.0220921
Rights and permissions
About this article
Cite this article
Second varicella vaccine dose worth extra cost in Turkey. PharmacoEcon Outcomes News 835, 30 (2019). https://doi.org/10.1007/s40274-019-6167-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6167-0